&lt;p&gt;In Quest of Pathognomonic/Endophenotypic Markers of Attention Deficit Hyperactivity Disorder (ADHD): Potential of EEG-Based Frequency Analysis and ERPs to Better Detect, Prevent and Manage ADHD&lt;/p&gt;

Miranda, Priya; Cox, Christopher D.; Alexander, Michael P.; Danev, Slav; Lakey, Jonathan R. T.

doi:10.2147/mder.s241205

Cited by 10 publications

(8 citation statements)

References 233 publications

(241 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since July 6th 1924, when the first EEG was recorded, it has evolved from being an add-on tool in the diagnosis of brain health, to an instrument that is used for diagnosis, diseasestaging, evaluation of prognosis, monitoring the course of treatment (pharmacotherapy and chemotherapy), and as a therapeutic tool [14][15][16][17][18][19][20][21][22][23]. The EEG allows for clinical decision making and non-invasive assessment of the functioning of the 4mm thick cerebral cortex, which governs our mental, neurological, neuromuscular and physiological well-being [14,15].…”

Section: The Eegmentioning

confidence: 99%

The “Tipping Point” : When Electroencephalography (EEG), Quantitative EEG (QEEG) and Standardized Low Resolution Brain Electromagnetic Tomography (sLORETA) in COVID Went From “Ceasure” To “Non- Priority” To “First-Line” Tool in Triage, Diagnosis, Monitoring and Therapy

Miranda,

Danev,

Alexander

et al. 2024

Neuro Neurosci

View full text Add to dashboard Cite

On the threshold of the COVID outbreak; electroencephalography (EEG) was used in diagnosis, crossborder disease differential diagnosis, disease-staging, monitoring of treatment, sedation and coma, in neuro-therapy and in declaration of brain death. EEG, quantitative EEG (QEEG), and standardized low resolution brain electromagnetic tomography (sLORETA) use entered the doldrums; reaching near “ceasure” due to COVID restrictions. Between 2020-2023, EEG use tipped, going from “Ceasure” to “First-Line” tool in triage, diagnosis, monitoring and therapy due to neurological, neurocognitive, neuropsychiatric, and neuromuscular sequelae of para- or acute- and post-COVID-19. The present paper will discuss this “Tipping point” in EEG, QEEG and sLORETA use.

show abstract

Section: The Eegmentioning

confidence: 99%

The “Tipping Point” : When Electroencephalography (EEG), Quantitative EEG (QEEG) and Standardized Low Resolution Brain Electromagnetic Tomography (sLORETA) in COVID Went From “Ceasure” To “Non- Priority” To “First-Line” Tool in Triage, Diagnosis, Monitoring and Therapy

Miranda,

Danev,

Alexander

et al. 2024

Neuro Neurosci

View full text Add to dashboard Cite

show abstract

“…Moreover, a recent study of nearly 28 000 twins estimated the genetic correlation ( r g ) between clinically-diagnosed ADHD and parent-rated ADHD symptoms at 0.56 and reported that 89% of this association could be attributed to genetic factors (Taylor et al, 2019). Twin and family studies have also elucidated the etiology underlying several cognitive and neurobiological features associated with ADHD (for reviews on current understanding of the neurobiology of ADHD, see Faraone et al, 2021; Miranda, Cox, Alexander, Danev, & Lakey, 2020). ADHD or ADHD traits share genetic factors with various executive functions such as reaction time variability and response inhibition (Crosbie et al, 2013; Kuntsi et al, 2010, 2014; Michelini et al, 2021; Tye, McLoughlin, Kuntsi, & Asherson, 2011) as well as brain-based electroencephalographic (EEG) measures (McLoughlin, Palmer, Rijsdijk, & Makeig, 2014; Michelini et al, 2021; Tye et al, 2011, 2012, 2014).…”

Section: Quantitative Genetic Studies Of Adhdmentioning

confidence: 99%

Insights into attention-deficit/hyperactivity disorder from recent genetic studies

et al. 2021

View full text Add to dashboard Cite

Attention-deficit/hyperactivity disorder (ADHD) is a common and highly heritable neurodevelopmental disorder (NDD). In this narrative review, we summarize recent advances in quantitative and molecular genetic research from the past 5–10 years. Combined with large-scale international collaboration, these advances have resulted in fast-paced progress in understanding the etiology of ADHD and how genetic risk factors map on to clinical heterogeneity. Studies are converging on a number of key insights. First, ADHD is a highly polygenic NDD with a complex genetic architecture encompassing risk variants across the spectrum of allelic frequencies, which are implicated in neurobiological processes. Second, genetic studies strongly suggest that ADHD diagnosis shares a large proportion of genetic risks with continuously distributed traits of ADHD in the population, with shared genetic risks also seen across development and sex. Third, ADHD genetic risks are shared with those implicated in many other neurodevelopmental, psychiatric and somatic phenotypes. As sample sizes and the diversity of genetic studies continue to increase through international collaborative efforts, we anticipate further success with gene discovery, characterization of how the ADHD phenotype relates to other human traits and growing potential to use genomic risk factors for understanding clinical trajectories and for precision medicine approaches.

show abstract

“…Although studies on the use of EEG to identify biomarkers related to ADHD is promising, at the moment there are several difficulties. One of the main challenges is defining the ADHD population and the different sub-groups [93]. An alternative to EEG-based markers comes from studies from experimental psychology.…”

Section: Searching a Specific Phenotype Across Measurable Traitsmentioning

confidence: 99%

Traditional Scales Diagnosis and Endophenotypes in Attentional Deficits Disorders: Are We on the Right Track?

Jiménez-Soto¹,

Vargas²,

Díaz³

et al. 2021

ADHD - From Etiology to Comorbidity

View full text Add to dashboard Cite

The concept of ADHD has changed widely through the history of mental health classification manuals. In the past three decades, the number of ADHD diagnoses has hugely increased worldwide. One of the reasons to explain this fact could be the lack of precision, differentiation and adjust of the criteria and indicators of this disease. Research has detected as well, some subjectivity bias in the traditional assessment (based in questionnaires and behavioral scales), which is affecting to the precision in the diagnose and to the further adjustment to the treatment. In this regard, these diagnoses are based in symptoms but not in etiology of the disorder. Therefore, different disorders will share the same treatment, regardless etiology. A different approach is based on the study of vulnerable traits associated with impulsivity and attentional deficit. In a quantitative fashion; these traits could be used to define a specific endophenotype. This view would allow us a more precise medical/psychological assessment focus on patient along the life spam, avoiding a diagnostic based on the number of symptoms. Here, we discuss about the differences between traditional diagnosis scales and the possibilities to find endophenotypes in order to address a specific treatment.

show abstract

<p>In Quest of Pathognomonic/Endophenotypic Markers of Attention Deficit Hyperactivity Disorder (ADHD): Potential of EEG-Based Frequency Analysis and ERPs to Better Detect, Prevent and Manage ADHD</p>

Cited by 10 publications

References 233 publications

The “Tipping Point” : When Electroencephalography (EEG), Quantitative EEG (QEEG) and Standardized Low Resolution Brain Electromagnetic Tomography (sLORETA) in COVID Went From “Ceasure” To “Non- Priority” To “First-Line” Tool in Triage, Diagnosis, Monitoring and Therapy

The “Tipping Point” : When Electroencephalography (EEG), Quantitative EEG (QEEG) and Standardized Low Resolution Brain Electromagnetic Tomography (sLORETA) in COVID Went From “Ceasure” To “Non- Priority” To “First-Line” Tool in Triage, Diagnosis, Monitoring and Therapy

Insights into attention-deficit/hyperactivity disorder from recent genetic studies

Traditional Scales Diagnosis and Endophenotypes in Attentional Deficits Disorders: Are We on the Right Track?

Contact Info

Product

Resources

About